Benzinga
Benzinga
Benzinga
sábado, septiembre 19

Palisade Bio Inc

PALINASDAQ
Trade with Public
Trade with Public
$1.59
-0.11-6.47%
al cierre: Sep 18, 5:00 PM EST
$1.61
0.021.26%
After hour: 7:58 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Palisade Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palisade Bio (PALI).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

9Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$11Upside to Avg. PT+555.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Jul 23, 2026OppenheimerLeland GershellInitiateOutperform$8
Apr 9, 2026Wolfe ResearchAndy ChenInitiateOutperform$7
More with Benzinga EdgeGet Access

Analyst Ratings News

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Vandana Singh

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.
Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved